journal
MENU ▼
Read by QxMD icon Read
search

Cardiovascular Drugs and Therapy

journal
https://www.readbyqxmd.com/read/29790056/a-10-year-trend-in-statin-use-among-older-adults-in-australia-an-analysis-using-national-pharmacy-claims-data
#1
Richard Ofori-Asenso, Jenni Ilomäki, Ella Zomer, Andrea J Curtis, Sophia Zoungas, Danny Liew
BACKGROUND: Statins have become standard of care in the prevention and treatment of atherosclerotic cardiovascular disease. The objective of this study was to examine the trends in statin use among Australians aged ≥ 65 years for the period 2007-2016. METHODS: Data from the Pharmaceutical Benefits Scheme covering a 10% random sample of the Australian population were analysed. The 1-year prevalence and incidence of statin use were determined for each year, as were the percentage of statin dispensations according to statin type or intensity and the percentage of new users prescribed each statin type or intensity...
May 23, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29766336/ischaemic-preconditioning-protects-cardiomyocytes-from-anthracycline-induced-toxicity-via-the-pi3k-pathway
#2
Angshuman Maulik, Sean M Davidson, Izabela Piotrowska, Malcolm Walker, Derek M Yellon
PURPOSE: Anthracyclines cause chronic irreversible cardiac failure, but the mechanism remains poorly understood. Emerging data indicate that cardiac damage begins early, suggesting protective modalities delivered in the acute stage may confer prolonged benefit. Ischaemic preconditioning (IPC) activates the pro-survival reperfusion injury salvage kinase (RISK) pathway which involves PI3-kinase and MAPK/ERK1/2. METHODS: We investigated whether simulated IPC (sIPC), in the form of a sublethal exposure to a hypoxic buffer simulating ischaemic conditions followed by reoxygenation, protects primary adult rat cardiomyocytes against anthracycline-induced injury...
May 15, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29766335/ticagrelor-versus-clopidogrel-as-part-of-dual-or-triple-antithrombotic-therapy-a-systematic-review-and-meta-analysis
#3
Ioannis Andreou, Alexandros Briasoulis, Christos Pappas, Ignatios Ikonomidis, Dimitrios Alexopoulos
PURPOSE: Clopidogrel is the standard P2Y12 receptor inhibitor used in patients requiring both antiplatelet therapy and oral anticoagulation (OAC). We investigated the safety and efficacy of ticagrelor as an alternative to clopidogrel in patients on OAC. METHODS: A systematic electronic literature search was performed in MEDLINE, EMBASE, and the Cochrane Library for randomised controlled studies that examined the relative safety and efficacy of clopidogrel versus ticagrelor among patients requiring therapy with antiplatelet agents plus OAC...
May 15, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29713851/assessment-of-complementary-treatment-with-yiqi-fumai-lyophilized-injection-on-acute-decompensated-ischemic-heart-failure-act-adihf-rationale-and-design-of-a-multicenter-randomized-controlled-trial
#4
Xianliang Wang, Zhiqiang Zhao, Yazhu Hou, E Tang, Guoyuan Zhao, Shuai Wang, Yingfei Bi, Chengliang Zhong, Ming Ren, Junhua Zhang, Jingyuan Mao, Boli Zhang
BACKGROUND: Heart failure (HF) is the end stage of many heart diseases, and ischemic heart disease (IHD) is the primary cause. Yiqi Fumai lyophilized injection, a contemporary Chinese medicine preparation, widely used in the treatment of IHF patients, shows clinical efficacy on improving symptoms and cardiac function, but the quality of the current literature does not address multiple important issues. This article describes a protocol for assessment of complementary treatment with Yiqi Fumai lyophilized injection in acute decompensated IHD...
April 30, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29713852/correction-to-assessment-of-the-1-of-patients-with-consistent-15-reduction-in-low-density-lipoprotein-cholesterol-pooled-analysis-of-10-phase-3-odyssey-alirocumab-trials
#5
Harold E Bays, Robert S Rosenson, Marie T Baccara-Dinet, Michael J Louie, Desmond Thompson, G Kees Hovingh
The original version of this article unfortunately contained a mistake in the Discussion section.
April 27, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29679303/do-the-sglt-2-inhibitors-offer-more-than-hypoglycemic-activity
#6
REVIEW
Eduardo Flores, Carlos G Santos-Gallego, Nely Diaz-Mejía, Juan Jose Badimon
Type 2 diabetes mellitus (T2DM) is one of the most common chronic health conditions in the USA; it affects approximately 10% of adults with up to one-quarter being undiagnosed. T2DM is associated with substantial cardiovascular (CV) morbidity and mortality. T2DM is a pathological condition characterized by elevated levels of glucose and associated with high CV risk. Traditional hypoglycemic drugs have demonstrated their capability for effective and maintained management of high glucose levels, but they have not significantly impacted on the incidence of CV events...
April 20, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29679302/association-of-abnormal-serum-potassium-levels-with-arrhythmias-and-cardiovascular-mortality-a-systematic-review-and-meta-analysis-of-observational-studies
#7
REVIEW
Liesa K Hoppe, Dana C Muhlack, Wolfgang Koenig, Prudence R Carr, Hermann Brenner, Ben Schöttker
PURPOSE: To provide the first systematic review and meta-analysis of observational studies on the association of abnormal serum potassium and cardiovascular outcomes. METHODS: Medline and ISI Web of Knowledge were systematically searched from inception until November 24, 2017. Data synthesis of relevant studies was performed using random effects model meta-analyses. RESULTS: Meta-analyses included 310,825 participants from 24 studies. In the older general population, low serum potassium was associated with a 1...
April 20, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29679301/contemporary-antithrombotic-treatment-in-patients-with-non-valvular-atrial-fibrillation-undergoing-percutaneous-coronary-intervention-rationale-and-design-of-the-greek-antiplatelet-atrial-fibrillation-grape-af-registry
#8
Ioanna Xanthopoulou, Vasiliki-Maria Dragona, Periklis Davlouros, Costas Tsioufis, Efstathios Iliodromitis, Dimitrios Alexopoulos
BACKGROUND: Approximately 5 to 7% of patients undergoing percutaneous coronary intervention (PCI) for the treatment of coronary artery disease require chronic oral anticoagulation (OAC) on top of aspirin and a P2Y12 receptor antagonist, mainly due to non-valvular atrial fibrillation (AF). The advent of non-vitamin K antagonist oral anticoagulants (NOACs) increased treatment options, while there is cumulative evidence that dual combination of a NOAC and a P2Y12 receptor antagonist attenuates risk of bleeding, compared to traditional triple therapy, consisting of a vitamin K antagonist (VKA), aspirin, and a P2Y12 receptor antagonist, without significantly compromising efficacy...
April 20, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29656359/myocardial-infarct-size-reduction-provided-by-local-and-remote-ischaemic-preconditioning-references-values-from-the-hatter-cardiovascular-institute
#9
Xavier Rossello, Zhenhe He, Derek M Yellon
PURPOSE: To accurately estimate the effect size of both local or classic ischaemic preconditioning (IPC) and remote ischaemic preconditioning (RIPC) using a pooling data set of 91 animals. METHODS: We combined all the available mouse data collected from our Institute over the last 3 years regarding (i) local IPC (4 cycles of 5 min of global ischaemia/reperfusion injury, IRI, followed by 35-min ischaemia and 2-h reperfusion) in the Langendorff-isolated perfused mouse heart model and (ii) RIPC (3 cycles of 5 min of limb occlusion followed by 40-min ischaemia and 2-h reperfusion) in the in vivo mouse model...
April 14, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29633048/old-drugs-for-new-indications-in-cardiovascular-medicine
#10
REVIEW
Yaron Arbel, Wael Abuzeid, Robert S Rosenson, Alanna Weisman, Michael E Farkouh
Inflammation participates in the initiation and progression of atherosclerotic cardiovascular disease, and it is a critical inciting factor leading to acute ischemic events. Evidence has shown that certain anti-inflammatory medications used to treat non-atherosclerotic inflammatory diseases reduce cardiovascular events. This article reviews evidence that commonly used anti-inflammatory therapies (colchicine, allopurinol, methotrexate), reduce cardiovascular events. We discuss potential mechanisms of action, efficacy, and safety of these therapies and propose a clinical trials design to investigate their efficacy...
April 10, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29627892/assessment-of-the-1-of-patients-with-consistent-15-reduction-in-low-density-lipoprotein-cholesterol-pooled-analysis-of-10-phase-3-odyssey-alirocumab-trials
#11
Harold E Bays, Robert S Rosenson, Marie T Baccara-Dinet, Michael J Louie, Desmond Thompson, G Kees Hovingh
PURPOSE: Clinical trials of statins and other lipid-lowering therapies (LLTs) often report large inter-individual variations in their effects on low-density lipoprotein cholesterol (LDL-C). We evaluated apparent hyporesponsiveness to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab (defined as < 15% LDL-C reduction from baseline at all timepoints) using data from 10 Phase 3 trials (3120 hypercholesterolemic patients). METHODS: This report assessed the LDL-C percent reduction from baseline at weeks 4-104 (depending on study), and alirocumab serum levels and antidrug antibodies, in patients with apparent hyporesponsiveness...
April 7, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29623481/effect-of-antazoline-on-electrophysiological-properties-of-atrial-muscle-and-conduction-system-of-the-heart
#12
Bartłomiej Jacek Bińkowski, Marcin Makowski, Paweł Kubiński, Andrzej Lubiński
PURPOSE: Antazoline is a first-generation antihistaminic agent with additional anticholinergic properties and antiarrhythmic potential. Recent data shows its high effectiveness in sinus rhythm restoration among patients with paroxysmal atrial fibrillation. The effect of antazoline on electrophysiological parameters of the heart in vivo has not yet been examined. The aim of this study was to evaluate changes in electrophysiological parameters of the heart muscle and conduction system as a response to increasing doses of antazoline...
April 6, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29589153/an-exploratory-study-of-dapagliflozin-for-the-attenuation-of-albuminuria-in-patients-with-heart-failure-and-type-2-diabetes-mellitus-dapper
#13
Fumiki Yoshihara, Miki Imazu, Toshimitsu Hamasaki, Toshihisa Anzai, Satoshi Yasuda, Shin Ito, Haruko Yamamoto, Kazuhiko Hashimura, Yoshio Yasumura, Kiyoshi Mori, Masataka Watanabe, Masanori Asakura, Masafumi Kitakaze
BACKGROUND AND AIMS: Sodium-dependent glucose transporter-2 (SGLT-2) inhibitors, which are anti-diabetic drugs, reportedly decrease the incidence of cardiovascular events in high-risk patients with cardiovascular diseases, and thus chronic heart failure (CHF). SGLT-2 inhibitors also decrease albuminuria in patients with type 2 diabetes mellitus (T2D). Since albuminuria is a biomarker of not only chronic kidney disease but also cardiovascular events, we hypothesized that, among T2D patients with CHF, SGLT-2 inhibitors will decrease the extent of albuminuria and also improve CHF concomitantly...
March 28, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29582211/the-caspase-1-inhibitor-vx-765-protects-the-isolated-rat-heart-via-the-risk-pathway
#14
Helison Do Carmo, Sapna Arjun, Orlando Petrucci, Derek M Yellon, Sean M Davidson
PURPOSE: Protecting the heart from ischaemia-reperfusion (IR) injury is a major goal in patients presenting with an acute myocardial infarction. Pyroptosis is a novel form of cell death in which caspase 1 is activated and cleaves interleukin 1β. VX-785 is a highly selective, prodrug caspase 1 inhibitor that is also clinically available. It has been shown to be protective against acute IR in vivo rat model, and therefore might be a promising possibility for future cardioprotective therapy...
March 26, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29556862/pterostilbene-decreases-cardiac-oxidative-stress-and-inflammation-via-activation-of-ampk-nrf2-ho-1-pathway-in-fructose-fed-diabetic-rats
#15
Ramoji Kosuru, Vidya Kandula, Uddipak Rai, Swati Prakash, Zhengyuan Xia, Sanjay Singh
PURPOSE: Oxidative stress has a pivotal role in the pathogenesis of diabetes-associated cardiovascular problems, which has remained a primary cause of the increased morbidity and mortality in diabetic patients. It is of paramount importance to prevent the diabetes-associated cardiac complications by reducing oxidative stress with the help of nutritional or pharmacological agents. Pterostilbene (PT), the primary antioxidant in blueberries, has recently gained attention for its promising health benefits in metabolic and cardiac diseases...
March 20, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29516206/effect-of-anagliptin-and-sitagliptin-in-type-2-diabetic-patients-with-dyslipidemia-and-cardiovascular-risk-what-is-the-real-reason-behind-it
#16
EDITORIAL
Venu Gopal Jonnalagadda, Harish Prabhanna Char, Praveen Kumar Ankana
No abstract text is available yet for this article.
March 7, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29508169/combined-sglt2-and-dpp4-inhibition-reduces-the-activation-of-the-nlrp3-asc-inflammasome-and-attenuates-the-development-of-diabetic-nephropathy-in-mice-with-type-2-diabetes
#17
Yochai Birnbaum, Mandeep Bajaj, Hsiu-Chiung Yang, Yumei Ye
BACGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 inhibitors (DPP4I) are used to treat type 2 diabetes (T2DM). DPP4 inhibitors (DPP4) attenuate Nlrp3 inflammasome activation in the kidney. SGLT2 inhibition reduces inflammation and attenuates the progression of diabetic nephropathy (DN). The effects of dapagliflozin (Dapa) on the activation of the Nlrp3 inflammasome and the combined effect of SGLT2 and DPP4 on T2DM-induced inflammasome activation and progression of DN have not been previously studied...
March 5, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29679304/analytic-approaches-for-the-treatment-of-hyperhomocysteinemia-and-its-impact-on-vascular-disease
#18
REVIEW
Soo-Sang Kang, Robert S Rosenson
Homocysteine is an intermediary metabolite in the methionine cycle. Accumulation of homocysteine is caused either by mutation of relevant genes or by nutritional depletion of related vitamin(s). This review covers the historical background of hyperhomocysteinemia in which indispensable subjects in relation to underlying pathophysiological processes are discussed with the view of metabolism and genetics of folate and methionine cycles. This review emphasizes the unique role of homocysteine that is clearly distinct from other risk factors, particularly cholesterol in the development of vascular disease...
April 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29488142/safety-and-incidence-of-cardiovascular-events-in-chinese-patients-with-acute-coronary-syndrome-treated-with-ticagrelor-the-12-month-phase-iv-multicenter-single-arm-dayu-study
#19
Runlin Gao, Yongjian Wu, Hengliang Liu, Guohai Su, Zuyi Yuan, Aidong Zhang, Yong Wang, Zhirong Wang, Yan Wang, Huanyi Zhang, Yang Zheng, Lei Liu, Lijun Shen, Maria Leonsson-Zachrisson, Yaling Han
PURPOSE: Ticagrelor is an orally administered, reversibly binding, direct-acting P2Y12 receptor antagonist previously evaluated in several phase III trials. This phase IV, multicenter, single-arm trial assessed the safety and incidence of cardiovascular (CV) events with ticagrelor in Chinese patients experiencing an acute coronary syndrome (ACS). METHODS: Patients hospitalized with an ACS received ticagrelor (180 mg loading dose, 90 mg twice daily thereafter) plus low-dose aspirin (75-100 mg/day) for up to 12 months...
February 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29455345/the-antidiabetic-armamentarium-reducing-the-residual-cardiovascular-risk-with-hba-1c-v-lowering-medications-editorial-to-glp-1-receptor-agonists-and-cardiovascular-disease-a-meta-analysis-of-recent-cardiac-outcome-trials-by-jia-x-alam-m-ye-y-et-al
#20
EDITORIAL
journal
journal
29693
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"